Metformin does not prevent atherosclerotic cardiovascular disease

Craig D Williams
2017 Cardiovascular Disorders and Medicine  
The recent description of the mechanism of action of metformin at the cellular level offers the opportunity to revisit the question of whether or not metformin is beneficial in patients with atherosclerotic cardiovascular disease (ASCVD). In the context of newer, larger trials which examined the role of glycemic management in high risk patients with diabetes, the landmark UK Prospective Diabetes Study (UKPDS) and University Group Diabetes Program (UGDP) study are revisited. A close
more » ... n of these trials reveals that the apparent finding of ASCVD benefit for metformin in the UKPDS is likely the result of trial design rather than an antiatherogenic benefit from metformin. Correspondence to:
doi:10.15761/cdm.1000152 fatcat:ulg6olpfenb6fn4rbnk2243peu